Home / Tag Archives: pre-exposure prophlaxis

Tag Archives: pre-exposure prophlaxis

CSRA’s DynPort Vaccine Company Gets Orphan Drug Designation on Plague Vaccine

TYSONS CORNER, VA, March 10, 2017 — A subsidiary of CSRA (NYSE: CSRA) has secured orphan drug status from the Food and Drug Administration on a plague vaccine it is developing as a potential pre-exposure prophlaxis treatment against Yersinia pestis infection, ExecutiveBiz reported Thursday. The company said Wednesday the designation enables DynPort Vaccine Company to …

Read More »